Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call Transcript

Andrew Eriksen
Allele Capital Partners, LLC

All right. I think we’re live now, so let’s jump in. Thank you, everyone, for joining today, Scinai Immunotherapeutics corporate overview and 2026 midyear business update. My name is Andrew Eriksen. I’m a Managing Director here at Allele Capital, who works directly with the Scinai team, and we’re helping kind of put on this event today. So we’re going to run through a bit of the first half results that you might have noticed Scinai published just yesterday, review some of those financials, some of those business updates, and then Amir is going to give us a bit of an outlook for the rest of 2026 and why the team is ultimately really excited about what’s to come.

So without further ado, we’ll get into it, and then we’ll save the questions at the end. If you’re watching on LinkedIn or YouTube, there’s chat boxes for both of those platforms, so submit your questions, and we’ll get to those at the end of the conversation. So without further ado, let’s jump into the call here, Amir. Maybe what you can do is, I’m sure a lot of people on the call are familiar with who you are, but maybe just a quick background on yourself and your role at Scinai and then we can get into some of the first half details.

Amir Reichman
CEO & Director

Thank you very much, Andrew, and welcome, everybody, to our webinar today. I’m Amir Reichman. I have a biotechnology engineering master’s degree and an MBA from the Wharton School of Penn University. My background goes back more than 20 years